SIRT1 Is Downregulated in Gastric Cancer and Leads to G1-Phase Arrest Via NF- Κb/Cyclin D1 Signaling
Total Page:16
File Type:pdf, Size:1020Kb
Published OnlineFirst October 9, 2013; DOI: 10.1158/1541-7786.MCR-13-0214 Molecular Cancer Cell Cycle and Senescence Research SIRT1 Is Downregulated in Gastric Cancer and Leads to G1-phase Arrest via NF-kB/Cyclin D1 Signaling Qing Yang1, Bo Wang3, Wei Gao5, Shanying Huang4, Zhifang Liu2, Wenjuan Li1, and Jihui Jia1 Abstract Sirtuin 1 (SIRT1) is a class III histone/protein deacetylase, and its activation status has been well documented to have physiologic benefits in human health. However, the function of SIRT1 in cancer remains controversial. Here, the expression and role of SIRT1 in gastric cancer is delineated. SIRT1 was present in all normal gastric mucosa specimens; however, it was only present in a portion of the matched gastric cancer tumor specimens. In SIRT1- positive tumors, both mRNA and protein levels were downregulated as compared with the corresponding nonneoplastic tissue. Ectopic expression of SIRT1 inhibited cell proliferation, diminished clonogenic potential, and induced a G1-phase cell-cycle arrest, the effects of which were not apparent when a catalytic-domain mutant form of SIRT1 was introduced, suggesting that SIRT1 functions in gastric cancer are dependent on its deacetylase activity. Further evidence was obtained from depletion of SIRT1. At the molecular level, SIRT1 inhibited the transcription of Cyclin D1 (CCND1), and inhibition of NF-kB in SIRT1-depleted cells rescued Cyclin D1 expression. Furthermore, inhibition of either NF-kB or Cyclin D1 in SIRT1-depleted cells reversed the inhibitory effects of SIRT1. The inhibitory role of SIRT1 was also verified in vivo using xenografts. This work characterizes SIRT1 status and demonstrates its inhibitory function in gastric cancer development, which involves NF-kB/ Cyclin D1 signaling, offering a therapeutic role for SIRT1 activators. Implications: The inhibitory functions of SIRT1, which involve NF-kB/Cyclin D1 signaling, suggest the utility of SIRT1 activators in the prevention and therapy of gastric cancer. Mol Cancer Res; 11(12); 1497–507. Ó2013 AACR. Introduction curable disease with a high 5-year overall survival rate (3). On the basis of incidence and mortality rate, gastric cancer Therefore, studies about new diagnostic or prognostic mar- is among the top five leading causes of cancer worldwide. In kers and therapeutic targets for gastric cancer are urgently needed. 2008, there were approximately 12.7 million cancer cases þ worldwide, and gastric cancer accounted for 8% of all Sirtuin 1 (SIRT1), a class III NAD -dependent histone cancers (1). The majority of new gastric cancer cases occur deacetylase, is the mammalian homolog of yeast silent in Eastern Asia, Eastern Europe, and South America. information regulator 2. SIRT1 substrates include not only Although gastric cancer rates have decreased globally, it histones but also nonhistone proteins. Through these tar- remains high in developing countries, especially China (1, gets, SIRT1 plays a crucial role in multiple pathways such as 2). Most of the patients with gastric cancer are not diagnosed cellular metabolism, stress response, calorie restriction, and aging (4, 5). An abundance of recent data has demonstrated until they have reached advanced stages of the disease when, fi despite the use of conventional therapies such as surgery, that activation of SIRT1 has physiologic bene ts, including increased health and longevity, and assists in certain meta- chemotherapy, and radiotherapy, patients have a poor prog- – nosis. However, early-stage gastric cancer is a potentially bolic disorders (4 6). However, the function of SIRT1 in cancer is controversial. SIRT1 was initially regarded as a potential oncogene because of its first nonhistone substrate, 1 2 p53, a well-known tumor suppressor. SIRT1 deacetylates Authors' Affiliations: Institute of Pathogen Biology, Department of Biochemistry, Shandong University School of Medicine; 3Department of p53 with specificity for the C-terminal Lys382 residue and Traditional Chinese Medicine, 4Key Laboratory of Cardiovascular Re- silences p53 activity as a transcription factor (7, 8). In modeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Qilu Hospital, Shandong University; and addition, two tumor suppressors, hypermethylated in cancer 5Department of Pathology, Jinan Central Hospital, Jinan, China (HIC1) and deleted in breast cancer (DBC1), have been fi Note: Supplementary data for this article are available at Molecular Cancer identi ed as negative regulators of SIRT1 (9, 10). A recently Research Online (http://mcr.aacrjournals.org/). published study has provided new evidence for the role of Corresponding Author: Jihui Jia, Institute of Pathogen Biology, Shandong SIRT1 as a tumor promoter by describing a positive feedback University School of Medicine, Jinan 250012, China. Phone: 86-531-8838- loop between C-Myc and SIRT1 in hepatocellular carcino- 2672; Fax: 86-531-8838-2502; E-mail: [email protected] mas (11). However, studies from other laboratories have doi: 10.1158/1541-7786.MCR-13-0214 indicated that SIRT1 acts as a tumor suppressor. First, Ó2013 American Association for Cancer Research. acetylation of H3K56, a substrate for SIRT1, is increased www.aacrjournals.org 1497 Downloaded from mcr.aacrjournals.org on September 29, 2021. © 2013 American Association for Cancer Research. Published OnlineFirst October 9, 2013; DOI: 10.1158/1541-7786.MCR-13-0214 Yang et al. in multiple cancers (12). Second, SIRT1 has been reported performed for genes, including SIRT1, cyclin D1, and to play a key role in repairing DNA-breaks and maintaining b-actin as previously described (18). The sequences of the genome stability (13, 14). Moreover, SIRT1 has been shown amplification primers are listed in Supplementary Table S1. to suppress the growth of colon cancer by inhibiting E2F1 or The levels of SIRT1 mRNA in clinical specimens were b C -catenin (15, 16). The role of SIRT1 in oncogenic pro- calculated on the basis of the threshold cycle ( t) values gression seems to be specific for tumor type and signaling and normalization of b-actin expression using the 2ÀDDCt pathway involved. method (19). The mRNA expression of cyclin D1 was In this study, we investigated the expression and function normalized to b-actin relative to the control using the of SIRT1 in gastric cancer. We compared the expression of 2ÀDDCt method. Experiments were performed in triplicate SIRT1 between normal and malignant gastric tissues. Then and repeated three times. we analyzed cell viability, clonogenic potential, cell-cycle distribution, and apoptosis and investigated the mechanism Western blot analysis for how SIRT1 suppresses tumorigenesis. The inhibitory Total protein from the tumor specimens or cells was activity of SIRT1 on gastric cancer development was also extracted using RIPA lysis buffer (Beyotime) as previously evaluated in vivo. described (18). The protein concentration was determined using a BCA Protein Assay Kit (Pierce). The membrane was Materials and Methods probed with antibodies against SIRT1 and b-catenin Patients and tissue specimens (Abcam), cyclin D1, cyclin D2, cyclin D3, cyclin E1, Forty-four patients with primary gastric cancer were cyclin-dependent kinase (CDK)4, bcl-2, bax, caspase-3, included in this study, which was approved by the local NF-kB p65, and c-Jun (Cell Signaling Technology), cyclin ethics committee (No. 2011008 for Ethics Approval). The D2, p21, and p16 (Santa Cruz Biotechnology). Horseradish patients underwent gastrectomy at Jinan Central Hospital peroxidase (HRP)–conjugated anti-rabbit or -mouse anti- between 2011 and 2012. The tissue specimens were col- body was used as the secondary antibody. The protein bands lected and stored as previously described (17). There were 11 were visualized using an ECL system (Pierce). b-actin (Cell female patients and 33 male patients, with a median age of 60 Signaling Technology) served as a loading control. (range, 35–82). Details of patient and disease characteristics are documented in Table 1. Immunohistochemistry The tumor specimens from patients with gastric cancer and Cell lines, plasmids, and siRNA the nude mice were deparaffinized, rehydrated, and antigen Human gastric cancer cell lines AGS, MGC-803 (Cell retrieved. The antibodies against SIRT1 (1:200; Santa Cruz Resource Center, Shanghai Institute of Biochemistry and Biotechnology) and Ki67 (1:500; Abcam) were added to the Cell Biology at the Chinese Academy of Sciences, Shanghai, sections and then incubated overnight at 4C. HRP-conju- China), BGC-823, and SGC-7901 (China Center for Type gated anti-rabbit immunoglobulin G (IgG) and 3,30-diami- Culture Collection, Wuhan, China) were cultured in F12 nobenzidine (DAB) staining were used to visualize the (AGS) or RPMI 1640 (BGC-823, SGC-7901, and MGC- primary antibody. Then, the slides were counterstained with 803) containing 10% FBS, 100 U/mL penicillin and 2 hematoxylin and imaged by an Olympus light microscope mmol/L L-glutamine at 37 C in a humidified atmosphere using cellSens Dimension software. The percentages of Ki67- fi containing 5% CO2. Both of the cell banks routinely positive cells were counted under microscope (magni cation, perform cell line authentication by short tandem repeat Â400) and five fields were counted for each section. (STR) profiling and all of the cell lines were passaged in our laboratory for no more than 6 months after receipt. High- MTS assay purity cycloheximide (CHX; 3-[2-(3,5-dimethyl-2-oxocy- The CellTiter96 AQueous One Solution Cell Prolifera- clohexyl)2-hydroxyethyl-]-glutarimide) was purchased tion Assay (Promega) was performed to indicate cell prolif- from Beyotime, dissolved in dimethyl sulfoxide (DMSO), eration. Briefly, 2 Â 103 cells were seeded in a 96-well plate and added into the culture medium at a concentration of 20 and were allowed to grow for 24 hours. Twenty-four hours mg/mL. The vectors expressing wild-type SIRT1 (pECE- later, 20 mL MTS was added to each well. After incubation SIRT1) and the catalytic-domain mutant form of SIRT1 for 3 hours at 37 C, the absorbance at 490 nm was recorded (pECE-SIRT1-H363Y) were purchased from Addgene on a Varioskan Flash Multiplate Reader (Thermo Scientific).